Politwoops
Explore the Tweets They Didn't Want You to See
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office.
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office. If you think we're missing someone, please email us with their name, state, political party, office they hold or are seeking and, of course, their Twitter handle.
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.
RepHagan (R-Ohio)
@RepHagan
Josie gets the job done beautifully. Thanking God for my little Christmas helper! ❤️ https://t.co/qItXSXNF2T
MorriseyWV (R-W.Va.)
@MorriseyWV
During this holiday season, I am thankful to have such a terrific team in the AG’s office and continue to strive to be the best law firm in West Virginia. #wvag
SteveFDA (R-D.C.)
@SGottliebFDA
Thank you to the dedicated staff of #FDA and their efforts to advance and protect public health: In 2017 FDA notched an all-time record number of novel drug approvals and an all-time record number of generic drug approvals https://t.co/25u6vecTlc
RT @gophousemum: I have faith that @RepDonBacon will be able to convince Members across the aisle to support the DoD, if only to prevent th… QT @FoxNews: Defense cuts looming unless Congress takes action next month https://t.co/KZDnXT3o1A)
SteveFDA (R-D.C.)
@SGottliebFDA
1/3 There’s some lament re:orphan grants on secondary indications. But we also see promising uses of approved drugs in very rare diseases go unstudied. Could we change incentive structure when it comes to secondary indications to better target unmet need? QT @statnews: The Orphan Drug Act has created lots drugs for rare diseases. But, Scott Gottlieb says, the times may be changing. https://t.co/BBR4bsW1JZ)
SteveFDA (R-D.C.)
@SGottliebFDA
2/3 For example, could we narrow the population we target when it comes to orphan grants in secondary indications to better target ultra rare conditions; but at same time change incentive structure in that setting to coax more development when it comes to
SteveFDA (R-D.C.)
@SGottliebFDA
3/3 At #FDA, we hope to work on these and similar broader policy issues next year, to make sure we’re continuing to deliver on the great purpose and promise of the orphan drug program. We’ll be conducting new analysis in 2018 to support and inform sound p
RT @KTOOpubmedia: New oil estimate for NPR-A: It’s ‘HUGE' (the @Interior press release actually says it in all caps)… https://t.co/LO7902iIKU
SteveFDA (R-D.C.)
@SGottliebFDA
FDA and CTTI launch the Patient Engagement Collaborative. This new forum will bring together the patient community and regulators to discuss patient engagement across FDA’s product centers https://t.co/nmAHJcpOoP https://t.co/vCHhRN8ZCm
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.